| 1 | 08:00-08:15 |
Welcome And Introduction |
|
|||||||||
| 1 | 08:15-08:22 | Moderated Podium Presentation |
Engineered Biomimetic Nanoparticles Synergistically Sensitize Photodynamic-Immunotherapy for Bladder Cancer via Induction of Disulfidptosis |
|
|||||
| 2 | 08:25-08:32 | Moderated Podium Presentation |
A Retrospective study to compare the outcomes of transperitoneal and retroperitoneal approaches in subjects undergoing laparoscopic live donor nephrectomy |
|
|||||
| 3 | 08:35-08:42 | Moderated Podium Presentation |
Real-Time Deep Learning Prediction of an Expert-Defined Apical Dissection Line During Robot-Assisted Radical Prostatectomy |
|
|||||
| 4 | 08:45-08:52 | Moderated Podium Presentation |
Targeting SLC16A3 reverses lactate-driven immune dysfunction and immunotherapy resistance in ccRCC |
|
|||||
| 5 | 08:55-09:02 | Moderated Podium Presentation |
The Prognostic Significance of Young Age in Prostate Cancer: A Propensity Score-Matched Analysis of the SEER Database |
|
|||||
| 6 | 09:05-09:12 | Moderated Podium Presentation |
Neoadjuvant toripalimab plus axitinib for renal cell carcinoma with venous tumor thrombus: perioperative, oncological, and pathological outcomes |
|
|||||
| 7 | 09:15-09:22 | Moderated Podium Presentation |
An Anatomy-Based Classification System for Adrenal Tumors With Venous Tumor Thrombus |
|
|||||
| 8 | 09:25-09:32 | Moderated Podium Presentation |
Resection Margin Versus Tumour Base in Predicting Residual Disease Following En bloc Resection of Bladder Tumour: A Post-Hoc Analysis of the Multicentre EB-StaR Randomised Trial |
|
|||||
| 9 | 09:35-09:42 | Moderated Podium Presentation |
Antibiotic Prophylaxis Practices for Prostate Biopsies in India: Results from a Nationwide Multicentre Prospective Audit |
|
|||||
| 10 | 09:45-09:52 | Moderated Podium Presentation |
Photon-enhanced CT Prostatic Artery Reconstruction for Preoperative Guidance of Prostatic Artery Pre?occlusion to Preserve NVB During RALP |
|
|||||
| 1 | 10:30-10:37 | Moderated Podium Presentation |
Mast cell stabilization inhibits benign prostatic hyperplasia |
|
|||||
| 2 | 10:40-10:47 | Moderated Podium Presentation |
Long-Term Outcomes of Lingual Mucosal Graft Ureteroplasty for Complex Ureteral Stricture: A 10-Year Experience with 268 Cases |
|
|||||
| 3 | 10:50-10:57 | Moderated Podium Presentation |
Long-Term Renal and Bladder Outcomes Following Endoscopic Fulguration of Posterior Urethral Valves: A 20-Year Single-Center Experience |
|
|||||
| 4 | 11:00-11:07 | Moderated Podium Presentation |
Association Between Contrast Passage and Improvement in Hydronephrosis Grade Following Antegrade Double-J Stent Insertion in Stage IIIB Cervical Cancer Patients |
|
|||||
| 5 | 11:10-11:17 | Moderated Podium Presentation |
Ccl8 Accelerates Testicular Aging by Activating Nf-κB Signaling and Promoting Macrophage M1 Polarization |
|
|||||
| 6 | 11:20-11:27 | Moderated Podium Presentation |
Kidney transplantation in patients with urinary tract reconstruction |
|
|||||
| 7 | 11:30-11:37 | Moderated Podium Presentation |
Tubular Ferroptosis Promotes TGF-β1-Mediated Macrophage-to-Myofibroblast-like Remodeling in Obstructive Renal Fibrosis |
|
|||||
| 8 | 11:40-11:47 | Moderated Podium Presentation |
Pedicled Preputial Tube Urethroplasty for Long-segment Bulbar Urethral Necrosis after Failed Anastomotic Repair for Pelvic Fracture Urethral Injury |
|
|||||
| 9 | 11:50-11:57 | Moderated Podium Presentation |
Prediction of Outcomes in Pediatric Minimally Invasive Pyeloplasty Based on Explainable Machine Learning |
|
|||||
| 10 | 12:00-12:07 | Moderated Podium Presentation |
Low-pressure Versus High-pressure Hydrodistention in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS): A Randomised Controlled Trial |
|
|||||
| 1 | 12:00-12:05 |
Welcome and Introduction |
|
|||||||||
| 2 | 12:05-12:20 | Lecture |
Sixteen years of multinational experience in female genital fistula repair |
|
||||||||
| 3 | 12:20-12:35 | Lecture |
Management of urethral loss in females |
|
||||||||
| 4 | 12:35-12:50 | Lecture |
Management of vesicovaginal fistulas |
|
||||||||
| 5 | 12:50-12:55 |
Summary |
|
|||||||||
| 6 | 12:55-13:00 |
Closing Remarks |
|
|||||||||